An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 09 May 2016
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- 04 May 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 23 Apr 2014 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
- 23 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.